Trade BioNTech BNTX

Sell
 Buy

BioNTech live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

BioNTech News

2025 Jul 15, 12:10

US CPI June Data: Will Tariffs Sway the Fed's Rate Cut Decision?

2025 Jul 15, 08:10

Euroclear Warns EU: Investing Frozen Russian Assets Could Equal 'Confiscation'

Ghko B 2025 Jul 14, 16:00

Stellar Price (XLM) Surges 110% in 6 Days: How to Trade Stellar CFDs?

crypto
Frances Wang 2025 Jul 14, 16:00

Cryptos to Watch: SOLUSD Prediction, ETH Price, XRP News, Dogecoin Price

crypto cfd trading
Ghko B 2025 Jul 14, 16:00

CRWV Stock Jumps 209% in 3 Months: How to Trade CRWV Stock CFDs?

stocks
Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Latest news

Show more
Emma Rose 2025 Jul 15, 13:20

US Inflation & Tariffs: Will the Fed Hike Rates?

Emma Rose 2025 Jul 15, 12:20

Mnuchin Suggests Powell Resign from Fed Board After Chairmanship

Emma Rose 2025 Jul 15, 10:20

Trump Encouraged Ukraine to Strike Deep Inside Russia: A Shift in Strategy and Potential Escalation

liam james 2025 Jul 15, 09:20

Trump's Tariff Threat: Europe Scrambles to Avert a Full-Blown Trade War

Sophia Claire 2025 Jul 15, 06:20

US Inflation: CPI, Tariff Impact, and Federal Reserve Policy

liam james 2025 Jul 15, 06:20

Gold Price Outlook: Tariffs, Central Banks, and Supply Dynamics

Noah Lee 2025 Jul 15, 02:20

Bitcoin Breaks Consolidation, Surges Above $120K Amid Regulatory Optimism

Emma Rose 2025 Jul 15, 01:20

Kevin Hassett Emerges as Potential Fed Chair Under Trump: An Analysis

Info

Spread

0.8738

Spread (%)

0.7930 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Wednesday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

26683846656

Shares Outstanding

240395008

Earnings Date (Next)

0000-00-00

Div Yield

2022-06-17

Ex-Dividend Date

2022-06-02

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.73

Learn more about this instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Jul 14, 16:00

NBIS Stock Jumped over 17%: What Happened to Nebius Group?

Shares Stocks
Ghko B 2025 Jul 14, 16:00

XLM Outperforms Bitcoin: Can Stellar Price (XLM) Reach $1?

Crypto
Frances Wang 2025 Jul 14, 16:00

Crypto CFD Trading for Beginners: Ethereum CFD, XRP CFD, Solana CFD

Crypto CFD Trading
Trustpilot